title: Review of airway illnesses by kytococcus and rothia and a look at inhalatory vancomycin as a treatment support.
abstract: Seriously compromised patients may acquire deep airway ailments by Gram positive, commensal bacteria including Kytococcus and Rothia, pathogenic tracts of which still remain quite unexplored. Resistances they express have been poorly investigated over the years, and no published guidelines for susceptibility testing and antibiotic therapy exist. We would therefore revise the current knowledge about these opportunistic organisms' clinical impact, as well as discuss on recent patents focusing on lung infection management. Particularly, these deal with the use of inhalatory vancomycin, even as lipidic complex, that appears a promising adjunctive treatment to systemic antimicrobials.
authors.affiliation: Clinical Microbiology and Virology, Department of Transfusion Medicine, Spirito Santo Hospital, Pescara (Pe), Italy. vincsavi@yahoo.it
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Savini
authors.forename: Chiara
authors.initials: C
authors.lastname: Catavitello
authors.forename: Gioviana
authors.initials: G
authors.lastname: Masciarelli
authors.forename: Daniela
authors.initials: D
authors.lastname: Astolfi
authors.forename: Andrea
authors.initials: A
authors.lastname: Balbinot
authors.forename: Azaira
authors.initials: A
authors.lastname: Bianco
authors.forename: Fabio
authors.initials: F
authors.lastname: Febbo
authors.forename: Claudio
authors.initials: C
authors.lastname: D'Amario
authors.forename: Domenico
authors.initials: D
authors.lastname: D'Antonio
mesh_terms: D000280:Administration, Inhalation; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D006094:Gram-Positive Bacteria / Q000187:drug effects / Q000472:pathogenicity*; D006801:Humans; D012140:Respiratory Tract Diseases / Q000188:drug therapy* / Q000382:microbiology*; D014640:Vancomycin / Q000008:administration & dosage*
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin